NUK - logo
E-viri
Recenzirano Odprti dostop
  • CD163+ tumor‐associated mac...
    Ramos, Rodrigo Nalio; Rodriguez, Céline; Hubert, Margaux; Ardin, Maude; Treilleux, Isabelle; Ries, Carola H; Lavergne, Emilie; Chabaud, Sylvie; Colombe, Amélie; Trédan, Olivier; Guedes, Henrique Gomes; Laginha, Fábio; Richer, Wilfrid; Piaggio, Eliane; Barbuto, José Alexandre M; Caux, Christophe; Ménétrier‐Caux, Christine; Bendriss‐Vermare, Nathalie

    Clinical & translational immunology, 2020, Letnik: 9, Številka: 2
    Journal Article

    Objectives The accumulation of tumor‐associated macrophages (TAMs) is correlated with poor clinical outcome, but the mechanisms governing their differentiation from circulating monocytes remain unclear in humans. Methods Using multicolor flow cytometry, we evaluated TAMs phenotype in 93 breast cancer (BC) patients. Furthermore, monocytes from healthy donors were cultured in the presence of supernatants from dilacerated primary tumors to investigate their differentiation into macrophages (MΦ) in vitro. Additionally, we used transcriptomic analysis to evaluate BC patients’ blood monocytes profiles. Results We observed that high intra‐tumor CD163‐expressing TAM density is predictive of reduced survival in BC patients. In vitro, M‐CSF, TGF‐β and VEGF from primary tumor supernatants skewed the differentiation of healthy donor blood monocytes towards CD163highCD86lowIL‐10high M2‐like MΦ that strongly suppressed CD4+ T‐cell expansion via PD‐L1 and IL‐10. In addition, blood monocytes from about 40% of BC patients displayed an altered response to in vitro stimulation, being refractory to type‐1 MΦ (M1‐MΦ) differentiation and secreting higher amounts of immunosuppressive, metastatic‐related and angiogenic cytokines. Aside from showing that monocyte transcriptome is significantly altered by the presence of BC, we also demonstrated an overall metabolic de‐activation in refractory monocytes of BC patients. In contrast, monocytes from sensitive BC patients undergoing normal M1‐MΦ differentiation showed up‐regulation of IFN‐response genes and had no signs of metabolic alteration. Conclusion Altogether, our results suggest that systemic factors skew BC patient blood monocytes towards a pro‐metastatic profile, resulting in the accumulation of further polarised CD163high TAMs resembling type‐2 MΦ (M2‐MΦ) in the local BC microenvironment. These data indicate that monitoring circulating monocytes in BC patients may provide an indication of early systemic alterations induced by cancer and, thus, be instrumental in the development of improved personalised immunotherapeutic interventions. The mechanisms governing suppressive tumor‐associated macrophage (TAM) generation from circulating monocytes remain unclear in humans. In this study, we identify tumor‐derived M‐CSF, TGF‐β and VEGF as key factors skewing monocytes towards immunosuppressive CD163highCD86lowIL‐10high M2‐like macrophages (MΦ). We also describe an intrinsic metabolic de‐activation in breast cancer (BC) patient monocytes refractory to type‐1 MΦ (M1‐MΦ) differentiation that contrast with the active intrinsic IFN‐signalling pathway detected in sensitive BC patient monocytes undergoing normal M1‐MΦ differentiation. Thus, the combined local and systemic skewing of monocytes may give rise to the accumulation of suppressive M2‐like TAMs, contributing to the immune response failure and impacting on BC patient outcome.